Active Biotech AB

The Sunitinib Malate market is projected to grow from $109.1M in 2023 to $208M by 2030, driven by rising cancer incidence, targeted therapy adoption, and precision oncology advancements. Sunitinib, a multi-kinase inhibitor, is pivotal in treating RCC and GIST, with ongoing research focusing on combination therapies and biomarker development to enhance efficacy and overcome resistance.